Trials / Active Not Recruiting
Active Not RecruitingNCT06519097
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
A Randomized, Placebo-Controlled Trial of Tocotrienol in the Prevention of Pancreatic Intraductal Papillary Mucinous Neoplasm Progression
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vitamin E Delta Tocotrienol | Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration. 400 mg orally, twice daily |
| OTHER | Placebo | Placebo contains no active ingredients. 465 mg pure olive oil orally, twice daily |
Timeline
- Start date
- 2024-07-09
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2024-07-25
- Last updated
- 2025-11-13
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06519097. Inclusion in this directory is not an endorsement.